Our data concluded: miRNA-569 modulates the NUSAP1/ZEB1 signaling axis, exert anti-tumor function, which is expected to be the clinical therapeutic target of pancreatic cancer. This evidence concerns the gene ZEB1 and familial pancreatic carcinoma.